Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristine Kucera

Physician Assistant Melissa, TX Physician Assistant

NPI 1699970368 CMS profile 11249643

3041 Washington Drive, Suite 400, Melissa, TX 75454

Open in the dashboard

General payments

$796,719

2,028 records reported · program years 2021–2025

Research payments

$16,410

Paid to them · 10 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristine Kucera of Melissa, TX is reported in the CMS Open Payments database as having received $796,719 across 2,028 general payments and $16,410 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $184,465 438
2024 General $167,102 459
2023 General $221,341 411
2022 General $162,059 467
2022 Research $10,390 6
2021 General $61,754 253
2021 Research $6,020 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristine Kucera
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kristine Kucera were reported at $184,465. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kristine Kucera Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $61,754 $132 $37–$438 $132
2022 $162,059 $155 $48–$522 $149
2023 $221,341 $167 $52–$557 $160
2024 $167,102 $178 $55–$600 $164
2025 $184,465 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $245,126 485 payments
  2. E.R. Squibb & Sons, L.L.C. $117,911 249 payments
  3. Janssen Biotech, Inc. $110,348 233 payments
  4. UCB, Inc. $72,800 167 payments
  5. Sun Pharmaceutical Industries Inc. $61,747 163 payments
  6. Amgen Inc. $56,184 146 payments
  7. LEO Pharma Inc. $53,051 107 payments
  8. Pfizer Inc. $17,802 50 payments
  9. Novartis Pharmaceuticals Corporation $16,949 75 payments
  10. Galderma Laboratories, L.P. $16,656 56 payments
  11. Other $28,145 297 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $529,000 335 payments
  2. Consulting Fee $105,536 96 payments
  3. Travel and Lodging $92,778 415 payments
  4. Food and Beverage $41,503 1,153 payments
  5. Honoraria $19,924 15 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $7,398 4 payments
  7. Education $581 10 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $168,020 296 payments
  2. TREMFYA $115,246 233 payments
  3. SOTYKTU $99,388 212 payments
  4. Bimzelx $65,618 125 payments
  5. SKYRIZI $63,964 141 payments
  6. Otezla $51,344 134 payments
  7. ILUMYA $43,507 120 payments
  8. ADBRY $38,894 82 payments
  9. Winlevi $17,984 39 payments
  10. CIBINQO $17,783 48 payments
  11. Other $59,217 628 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. AbbVie, Inc. $16,410 10 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

31

Median for Physician Assistant: 241

Drug cost

$343

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 17 $212
Triamcinolone Acetonide Generic 14 $131

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$56,918

Medicare's payments for the services billed

Medicare patients

104

Average age 73

Services billed

1,150

60 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 45%
Ischemic heart disease 28%
Diabetes 25%
Depression 23%
Atrial fibrillation 20%
Chronic kidney disease 16%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
$34,912 — —
RINVOQ
$31,311 — —
TREMFYA
$25,743 — —
Bimzelx
$21,809 — —
SKYRIZI
$17,301 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

2,038 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record